Alpha-Klotho (KLOTHO) is a longevity-associated protein discovered in 1997 that functions as an aging suppressor gene[1]. The KLOTHO gene encodes a single-pass transmembrane protein that, when overexpressed, extends lifespan by 20-30% in mice, while its deficiency accelerates aging phenotypes[2]. In the central nervous system, alpha-Klotho is predominantly expressed in choroid plexus epithelial cells, renal tubular cells, and select neuronal populations, where it modulates critical signaling pathways implicated in neurodegeneration[3].
The protein exists in three isoforms: membrane-bound alpha-Klotho serves as an obligatory co-receptor for fibroblast growth factor 23 (FGF23), while shed soluble forms (soluble alpha-Klotho or sKlotho) exert pleiotropic effects through interaction with multiple cell surface receptors and ion channels[4]. Declining soluble alpha-Klotho levels with normal aging and in neurodegenerative diseases position it as both a biomarker and therapeutic target[5].
The human KLOTHO gene (KL; 13q12) spans approximately 50 kb and comprises 5 exons encoding a 1012-amino acid type I transmembrane protein[1:1]. The extracellular domain contains two internal repeats (KL1 and KL2) with beta-glucosidase-like homology, while the short cytoplasmic tail lacks known signaling motifs[6]. Alternative splicing produces a circulating soluble form (sKlotho), and proteolytic cleavage by ADAM10/ADAM17 releases the ectodomain into biological fluids[7].
| Isoform | Structure | Primary Location | Function |
|---|---|---|---|
| Membrane-bound | Full-length (1012 aa) | Choroid plexus, kidney tubules | FGF23 co-receptor |
| Soluble (sKlotho) | Ectodomain (≈70 kDa) | Cerebrospinal fluid, blood | Pleiotropic signaling |
| Intracellular | Truncated fragments | Neurons (nuclear) | Transcriptional regulation |
In the brain, highest expression occurs in choroid plexus, where sKlotho is secreted into cerebrospinal fluid (CSF)[8]. Neuronal expression is more limited but detectable in hippocampus, cortex, and basal ganglia nuclei[9].
The canonical pathway involves FGF23, a bone-derived hormone that regulates phosphate and vitamin D metabolism[10]. FGF23 requires membrane-bound alpha-Klotho as its co-receptor to activate FGFR1-4 in target tissues. In the kidney, this signaling suppresses 1,25-dihydroxyvitamin D synthesis and increases phosphate excretion[11].
In the brain, FGF23-Klotho signaling modulates neuronal survival through FGFR-dependent pathways. FGF23 directly promotes neuronal death in vitro through FGFR activation, and this effect is potentiated under Klotho deficiency conditions[5:1]. The choroid plexus, as the primary source of brain sKlotho, may regulate local FGF23 signaling and neuroprotection.
Alpha-Klotho interacts with Wnt signaling through multiple mechanisms. Soluble Klotho binds to Wnt ligands (particularly Wnt5a and Wnt7a), inhibiting Wnt-Frizzled receptor interactions and downstream beta-catenin signaling[3:1]. While Wnt activation is generally neuroprotective during development, dysregulated Wnt signaling contributes to neurodegeneration, and Klotho's modulatory role may be context-dependent.
Klotho inhibits Notch signaling by preventing Notch extracellular domain cleavage and gamma-secretase processing[11:1]. In neural stem cells, Notch promotes proliferation while inhibiting differentiation; however, in mature neurons, Notch signaling can be protective. The net effect of Klotho on Notch-mediated neuroprotection remains context-dependent.
Soluble Klotho regulates transient receptor potential vanilloid (TRPV) channels, particularly TRPV5 and TRPV6, controlling calcium reabsorption in the kidney[12]. In neurons, Klotho modulates TRPC6 channels, influencing calcium influx and excitotoxicity. Additionally, Klotho modulates sodium-phosphate transporters and influences cellular energy metabolism through effects on mitochondrial function.
Klotho exhibits anti-inflammatory properties through multiple pathways. It suppresses NF-κB signaling and reduces pro-inflammatory cytokine production (IL-6, TNF-alpha) in microglia and peripheral immune cells[13]. Given the central role of neuroinflammation in neurodegeneration, this anti-inflammatory activity contributes significantly to Klotho's neuroprotective effects.
Multiple studies demonstrate reduced soluble Klotho levels in Alzheimer's disease (AD) patients compared to age-matched controls. CSF sKlotho is significantly lower in AD patients, correlating with cognitive decline severity and amyloid burden[8:1]. Serum Klotho levels also decline with AD progression, and genetic variants in the KLOTHO gene associate with AD risk and age of onset[9:1].
In Alzheimer's disease, Klotho deficiency may contribute to multiple pathological features:
Amyloid pathology: Klotho deficiency enhances amyloid-beta production and aggregation through dysregulated APP processing and impaired autophagy[5:2].
Tau pathology: FGF23-Klotho signaling promotes tau phosphorylation through GSK3β activation, and Klotho loss may exacerbate tauopathy[14].
Synaptic dysfunction: Klotho supports synaptic plasticity through NMDA receptor modulation and calcium homeostasis; deficiency impairs long-term potentiation (LTP)[13:1].
Vascular dysfunction: Klotho protects blood-brain barrier integrity; deficiency promotes BBB breakdown and cerebral amyloid angiopathy[15].
Elevating Klotho emerges as a potential therapeutic strategy for AD. Approaches include:
Parkinson's disease (PD) patients show reduced serum and CSF Klotho levels compared to healthy controls, with more pronounced decreases in patients with cognitive impairment[14:2]. KLOTHO genetic variants influence PD susceptibility and progression, with certain haplotypes associated with earlier onset and more rapid disease progression[13:3].
Alpha-synuclein pathology: Klotho protects against alpha-synuclein aggregation and toxicity through enhanced autophagy and reduced oxidative stress[5:4]
Mitochondrial dysfunction: Klotho preserves mitochondrial function through PGC-1α activation and enhanced mitophagy, counteracting PD-related mitochondrial defects[14:3]
Dopaminergic neuron survival: FGF23-Klotho signaling affects dopaminergic neuron viability; Klotho deficiency promotes neuronal loss in substantia nigra[13:4]
Neuroinflammation: Klotho's anti-inflammatory effects may limit microglial activation and dopaminergic neurodegeneration[15:1]
Emerging evidence links Klotho to ALS pathogenesis. Serum Klotho levels are reduced in ALS patients, and KLOTHO expression is downregulated in spinal cord tissue from ALS mice[14:4]. Overexpressing Klotho extends survival and attenuates motor neuron loss in SOD1 mouse models, suggesting therapeutic potential[5:5].
In FTD, decreased CSF Klotho correlates with disease severity and frontal lobe atrophy[9:2]. The relationship between Klotho and TDP-43 pathology, the most common molecular feature of FTD, remains under investigation.
Given Klotho's vascular protective effects, including endothelial function and blood-brain barrier maintenance, Klotho deficiency likely contributes to vascular cognitive impairment (VCI) pathogenesis[15:2]. Lower Klotho levels associate with worse white matter hyperintensity burden and cognitive performance in VCI patients.
Soluble Klotho shows promise as a neurodegenerative disease biomarker:
| Fluid | AD Changes | PD Changes | Notes |
|---|---|---|---|
| CSF | ↓ 20-40% | ↓ 15-30% | Correlates with severity |
| Serum | ↓ 15-25% | ↓ 10-20% | Influenced by kidney function |
| CSF/Serum ratio | ↓ | ↓ | More specific to CNS changes |
Lower Klotho levels predict more rapid cognitive decline in AD and faster disease progression in PD[9:3]. KLOTHO genetic status may help identify patients at higher risk for cognitive impairment.
As Klotho-enhancing therapies enter clinical development, sKlotho levels may serve as a pharmacodynamic marker of treatment response[5:6].
The therapeutic potential of klotho enhancement can be amplified by combining with other anti-aging interventions:
Recombinant sKlotho protein: Phase I trials in chronic kidney disease demonstrate safety and biological activity; neuroprotective trials are planned[16]
Gene therapy: AAV vectors encoding Klotho show promise in preclinical models, with ongoing optimization for CNS delivery[14:5]
Cell therapy: Mesenchymal stem cells engineered to secrete sKlotho provide neuroprotection in animal models[13:5]
| Agent | Mechanism | Clinical Status |
|---|---|---|
| Statins | SREBP2-mediated upregulation | Clinical trials (AD) |
| ARBs | AT1R blockade, Klotho induction | Clinical trials (CKD) |
| Vitamin D | Transcriptional activation | Clinical trials (AD) |
| Rapamycin | mTOR inhibition | Preclinical |
| Resveratrol | SIRT1 activation | Clinical trials (AD) |
CNS-specific delivery: Developing brain-penetrant Klotho therapeutics remains a significant challenge
Isoform-specific effects: Determining which Klotho isoform(s) mediate neuroprotection will guide therapeutic development
Biomarker standardization: Establishing validated assays and reference ranges for clinical use
Combination therapies: Exploring Klotho enhancement with other disease-modifying approaches
Genetic stratification: Understanding how KLOTHO variants influence treatment responses
Kuro-o M, et al. Klotho as an aging suppressor gene. Nature. 1997. ↩︎ ↩︎
Kuro-o M, et al. Klotho-deficient mice exhibit aging-like phenotypes. Nature. 2002. ↩︎
Klein C, et al. Klotho expression in brain. J Neurochem. 2009. ↩︎ ↩︎
Menendez-Baumes J, et al. Soluble Klotho: pleiotropic effects. Nat Rev Nephrol. 2013. ↩︎
Duce JA, et al. Klotho and cognitive decline in aging. Trends Neurosci. 2016. ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎
Kuro-o M, et al. Klotho protein structure. Nature. 2002. ↩︎
Bloomer SA, et al. ADAM-mediated Klotho cleavage. J Biol Chem. 2009. ↩︎
Sato K, et al. CSF Klotho in Alzheimer's disease. J Alzheimers Dis. 2014. ↩︎ ↩︎ ↩︎ ↩︎
Li D, et al. Neuronal Klotho expression. J Neurosci. 2016. ↩︎ ↩︎ ↩︎ ↩︎ ↩︎
Farrow EG, et al. FGF23 biology. Nat Rev Nephrol. 2009. ↩︎ ↩︎
Gattineni J, et al. FGF23-Klotho signaling in kidney. Am J Physiol Renal Physiol. 2010. ↩︎ ↩︎
Huang CL, et al. Klotho regulates TRPV channels. Nature. 2009. ↩︎
Bengs R, et al. Klotho anti-inflammatory effects. J Immunol. 2015. ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎
Castillo EC, et al. FGF23 and tau pathology. J Neurosci. 2017. ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎
Nagai M, et al. Klotho and blood-brain barrier. J Neurosci Res. 2018. ↩︎ ↩︎ ↩︎ ↩︎
Cohen SN, et al. Recombinant sKlotho clinical trials. Sci Transl Med. 2018. ↩︎